Investigating the role of gut bacteria in aseptic abscesses

Role of Gut Microbiota in the Pathophysiology of Aseptic Abscesses

Not applicable Interventional University Hospital, Clermont-Ferrand · NCT05537909

This study is trying to see if the bacteria in the gut play a role in causing aseptic abscesses by comparing samples from patients with the condition to those without it.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment60 (estimated)
Ages18 Years and up
SexAll
SponsorUniversity Hospital, Clermont-Ferrand Academic / other
Drugs / interventionsprednisone
Locations15 sites (Bordeaux and 14 other locations)
Trial IDNCT05537909 on ClinicalTrials.gov

What this trial studies

This study examines the relationship between gut microbiota and aseptic abscess syndrome, a condition characterized by deep abscesses without identifiable pathogens. It involves collecting biological samples such as stool, blood, saliva, and urine from patients diagnosed with the syndrome and matched controls. The samples will be analyzed to understand the microbiota composition and immune responses related to the condition. The goal is to uncover potential links between gut health and the pathophysiology of aseptic abscesses.

Who should consider this trial

Good fit: Ideal candidates include adults diagnosed with aseptic abscess syndrome who meet specific clinical criteria.

Not a fit: Patients with other types of abscesses or those not meeting the diagnostic criteria for aseptic abscess syndrome may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved understanding and treatment options for patients suffering from aseptic abscess syndrome.

How similar studies have performed: While the role of gut microbiota in various conditions has been studied, this specific investigation into aseptic abscess syndrome is novel and has not been extensively tested.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* For cases: adult patients meeting the diagnostic criteria for aseptic abscess syndrome described by André et al:
* Deep abscesses on radiological examination with neutrophilic features proven by pathological analysis of a surgical specimen or biopsy when performed
* Negative blood cultures, negative serological tests for bacteria, including always Yersinia enterocolitica, and, during surgery or aspiration, sterile pus (with standard cultures, BAAR and fungal tests) Failure of antibiotic therapy, when prescribed, after at least 2 weeks for conventional antibiotic therapy and at least 3 months for anti-tuberculosis treatment
* Rapid clinical improvement the day after the prescription of corticosteroids (at least 1/2 mg/kg prednisone or equivalent) followed by radiological improvement after 1 month of corticosteroids, sometimes in association with immunosuppressive treatments.

For controls: adult person living in the same environment as the case to which it is matched. Adult person living in the same household or near the patient.

For cases and controls:

* Ability to provide informed consent.
* Membership in the Social Security system.

Exclusion Criteria:

* Pregnant women. Incapable patients Patients deprived of liberty Antibiotic therapy administered within 6 weeks prior to inclusion.

Where this trial is running

Bordeaux and 14 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Aseptic Abscess SyndromeAseptic abscess syndromeComparative StudyPathophysiology
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.